137 related articles for article (PubMed ID: 24471694)
1. The full electron structure of the FKBP12/FK506 complex.
Rossetto AM; Zhou W; Pang X; Zhou L
J Biomol Struct Dyn; 2015; 33(2):388-94. PubMed ID: 24471694
[TBL] [Abstract][Full Text] [Related]
2. Differential Large-Amplitude Breathing Motions in the Interface of FKBP12-Drug Complexes.
Yang CJ; Takeda M; Terauchi T; Jee J; Kainosho M
Biochemistry; 2015 Dec; 54(47):6983-95. PubMed ID: 26561008
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of the RyR1-FKBP12 interaction.
Samsó M; Shen X; Allen PD
J Mol Biol; 2006 Mar; 356(4):917-27. PubMed ID: 16405911
[TBL] [Abstract][Full Text] [Related]
4. Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus).
Itoh S; Navia MA
Protein Sci; 1995 Nov; 4(11):2261-8. PubMed ID: 8563622
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the binding sites for the interactions between FKBP12 and intracellular calcium release channels.
Wen H; Kang S; Song Y; Song Y; Yang HJ; Kim MH; Park S
Arch Biochem Biophys; 2012 Jan; 517(1):37-42. PubMed ID: 22100703
[TBL] [Abstract][Full Text] [Related]
6. Conformational Entropy of FK506 Binding to FKBP12 Determined by Nuclear Magnetic Resonance Relaxation and Molecular Dynamics Simulations.
Solomentsev G; Diehl C; Akke M
Biochemistry; 2018 Mar; 57(9):1451-1461. PubMed ID: 29412644
[TBL] [Abstract][Full Text] [Related]
7. 2-Aryl-2,2-difluoroacetamide FKBP12 ligands: synthesis and X-ray structural studies.
Dubowchik GM; Vrudhula VM; Dasgupta B; Ditta J; Chen T; Sheriff S; Sipman K; Witmer M; Tredup J; Vyas DM; Verdoorn TA; Bollini S; Vinitsky A
Org Lett; 2001 Dec; 3(25):3987-90. PubMed ID: 11735566
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a cell model based on FKBP12 dimerization for screening of FK506-like neurotrophic small molecular compounds.
Xiao H; Wang LL; Shu CL; Yu M; Li S; Shen BF; Li Y
J Biomol Screen; 2006 Apr; 11(3):225-35. PubMed ID: 16490780
[TBL] [Abstract][Full Text] [Related]
9. Mean field analysis of FKBP12 complexes with FK506 and rapamycin: implications for a role of crystallographic water molecules in molecular recognition and specificity.
Rejto PA; Verkhivker GM
Proteins; 1997 Jul; 28(3):313-24. PubMed ID: 9223178
[TBL] [Abstract][Full Text] [Related]
10. Modeling the interaction between FK506 and FKBP12: a mechanism for formation of the calcineurin inhibitory complex.
Ivery MT; Weiler L
Bioorg Med Chem; 1997 Feb; 5(2):217-32. PubMed ID: 9061187
[TBL] [Abstract][Full Text] [Related]
11. FKBP12 dimerization mutations effect FK506 binding and differentially alter calcineurin inhibition in the human pathogen Aspergillus fumigatus.
Juvvadi PR; Bobay BG; Gobeil SMC; Cole DC; Venters RA; Heitman J; Spicer LD; Steinbach WJ
Biochem Biophys Res Commun; 2020 May; 526(1):48-54. PubMed ID: 32192767
[TBL] [Abstract][Full Text] [Related]
12. Computational full electron structure study of biological activity in Cyclophilin A.
Zhou W; Rossetto AM; Pang X; Zhou L
J Biomol Struct Dyn; 2016; 34(4):870-6. PubMed ID: 26264861
[TBL] [Abstract][Full Text] [Related]
13. Design and structure-based study of new potential FKBP12 inhibitors.
Sun F; Li P; Ding Y; Wang L; Bartlam M; Shu C; Shen B; Jiang H; Li S; Rao Z
Biophys J; 2003 Nov; 85(5):3194-201. PubMed ID: 14581219
[TBL] [Abstract][Full Text] [Related]
14. Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin.
Wilson KP; Yamashita MM; Sintchak MD; Rotstein SH; Murcko MA; Boger J; Thomson JA; Fitzgibbon MJ; Black JR; Navia MA
Acta Crystallogr D Biol Crystallogr; 1995 Jul; 51(Pt 4):511-21. PubMed ID: 15299838
[TBL] [Abstract][Full Text] [Related]
15. Differential responses of the backbone and side-chain conformational dynamics in FKBP12 upon binding the transition-state analog FK506: implications for transition-state stabilization and target protein recognition.
Brath U; Akke M
J Mol Biol; 2009 Mar; 387(1):233-44. PubMed ID: 19361439
[TBL] [Abstract][Full Text] [Related]
16. Intraligand hydrophobic interactions rationalize drug affinities for peptidyl-prolyl cis-trans isomerase protein.
Bizzarri M; Marsili S; Procacci P
J Phys Chem B; 2011 May; 115(19):6193-201. PubMed ID: 21500789
[TBL] [Abstract][Full Text] [Related]
17. Multi-timescale dynamics study of FKBP12 along the rapamycin-mTOR binding coordinate.
Sapienza PJ; Mauldin RV; Lee AL
J Mol Biol; 2011 Jan; 405(2):378-94. PubMed ID: 21073880
[TBL] [Abstract][Full Text] [Related]
18. Leveraging Fungal and Human Calcineurin-Inhibitor Structures, Biophysical Data, and Dynamics To Design Selective and Nonimmunosuppressive FK506 Analogs.
Gobeil SM; Bobay BG; Juvvadi PR; Cole DC; Heitman J; Steinbach WJ; Venters RA; Spicer LD
mBio; 2021 Dec; 12(6):e0300021. PubMed ID: 34809463
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the FK506 binding domain of Plasmodium falciparum FKBP35 in complex with FK506.
Kotaka M; Ye H; Alag R; Hu G; Bozdech Z; Preiser PR; Yoon HS; Lescar J
Biochemistry; 2008 Jun; 47(22):5951-61. PubMed ID: 18465874
[TBL] [Abstract][Full Text] [Related]
20. FK506-binding protein 12 ligands: a patent review.
Liu F; Wang YQ; Meng L; Gu M; Tan RY
Expert Opin Ther Pat; 2013 Nov; 23(11):1435-49. PubMed ID: 23957229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
